- Home
- SGLY vs ONCO Comparison
SGLY vs ONCO Comparison
Compare SGLY & ONCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SGLY | ONCO |
|---|---|---|
| Founded | 2001 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8M | 2.3M |
| IPO Year | 2008 | 2021 |
Fundamental Metrics
Financial Performance| Metric | SGLY | ONCO |
|---|---|---|
| Price | $0.42 | $1.88 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 15.1K | ★ 2.1M |
| Earning Date | 05-14-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 48.29 | 22.80 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,813,193.00 | $815,371.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.34 | $0.05 |
| 52 Week High | $1.46 | $7.65 |
Technical Indicators
Market Signals| Indicator | SGLY | ONCO |
|---|---|---|
| Relative Strength Index (RSI) | 47.22 | 58.22 |
| Support Level | $0.36 | $0.51 |
| Resistance Level | $0.43 | $2.01 |
| Average True Range (ATR) | 0.03 | 0.66 |
| MACD | 0.01 | 0.13 |
| Stochastic Oscillator | 29.23 | 22.27 |
Price Performance
Historical ComparisonAbout SGLY Singularity Future Technology Ltd.
Singularity Future Technology Ltd is an investment holding company. The company's operating segment includes Freight Logistics Services and Sale of Crypto-mining Machines. It generates maximum revenue from the Freight Logistics Services segment. Geographically, it derives a majority of its revenue from China.
About ONCO Onconetix Inc.
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. It has a product named Entadfi an FDA-approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology.